MELIFOZIN™

Drug class

Sodium–Glucose Co-Transporter 2 (SGLT2) inhibitor

Indications

• Type 2 Diabetes Mellitus – to improve glycemic control in adults
• Heart Failure – reduces risk of cardiovascular death and hospitalization in HFrEF (with or without diabetes)
• Chronic Kidney Disease (CKD) – slows progression and reduces risk of cardiovascular events in patients with CKD (with or without diabetes)

Mechanism of Action

• Inhibits SGLT2 in the proximal renal tubules ? reduces reabsorption of filtered glucose and sodium
• Leads to increased urinary glucose excretion ? lowers blood glucose levels
• Also causes mild osmotic diuresis and natriuresis ? beneficial effects on heart failure and kidney outcomes

Dosage

• Type 2 Diabetes: 10 mg orally once daily (can be taken with or without food)
• Heart Failure / CKD: 10 mg once daily
• Renal adjustment:
  • eGFR ?45 mL/min/1.73 m² ? No adjustment
  • eGFR 25–44 ? May continue for HF or CKD benefit (not recommended for initiating in T2DM solely for glycemic control)
  • eGFR <25 ? Not recommended for glycemic control; may continue for HF or CKD

Patient Advice

• Take once daily at the same time
• Maintain good genital hygiene to reduce infection risk
• Stay hydrated, especially in hot weather or during illness
• Report signs of genital pain/swelling, fever, or unexplained nausea/vomiting immediately
• Check ketones if feeling unwell, even if blood glucose is not high